Abstract : Cancer is one of the primary causes of deaths worldwide. Cervical cancer is one of the leading causes of cancer mortality, accounting for 17% of all cancer deaths among women aged between 30 and 69 years. Various inflammatory, premalignant and malignant lesions of cervix are known to occur. Screening for cancer is known to reduce mortality by early detection and treatment. Overexpression of epidermal growth factor receptor family is associated with aggressive biological behavior and metastatic potential with poor prognosis. In this prospective study, we will be discussing the role of HER-2/neu as a prognostic marker for premalignant and malignant cervical lesions. We studied 50 cases of premalignant and malignant lesions of the uterine cervix from September 2018 – August 2020. The specimens were received in 10% formalin which were fixed and stained by routine hematoxylin and eosin stains. Immunohistochemically stain using HER-2/neu monoclonal antibody marker was done on each one of them, all the cases showed grade 0 results as per 2014 ASCO/CAP guidelines. According to various studies conducted, Her2/neu expression in malignant uterine cervical carcinomas ranged from 0% to 100%. The reason for variation in expression of Her2/neu immunostain could possibly be due to small sample size, disparity in monoclonal antibody kits used as well as discrepancy in the procedure conducted. Therefore, studies with greater number of sample size are required in order to establish the prognostic significance of HER2/neu in pathogenesis of cervical cancers. Thus, to conclude, this oncogene may not be a future target for monoclonal antibody directed therapy for cervical cancer